Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)
Opening soon Phase 2 NCT07528417
Run by University of Manitoba · for 18 and older · All sexes
What this study is about
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life-changing blood cancers. Patients with MDS and AML commonly experience complications related to infection, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of levofloxacin (antibiotic) in MDS and AML patients to safely reduce the risk of infection. In this study 50% of patients will be randomized (like a flip of a coin) to receive levofloxacin and the other 50% will receive usual care (control). The primary objective of the trial is to demonstrate the feasibility of a pragmatic pilot trial necessary to inform our planned phase 3 trial. Additionally, the investigators will monitor both groups of patients to see if the investigators improve the risk and/or severity of infection. Levofloxacin is commonly used in other clinical settings but has not been studied in patients with MDS or AML receiving outpatient chemotherapy (ie, chemotherapy that can be given from clinic, rather than a hospital).
Who can join (things the study team will check)
✅ You may be able to join if…
- Age ≥ 18 years
- Diagnosis of myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, or acute myeloid leukemia MYELO-CAN ABX inclusion criteria:
- Initiation of hypomethylating agent-based chemotherapy
🚫 You may not be able to join if…
- Participant is deemed unlikely to survive >30 days (as determined by clinical team)
- Participant unable to provide informed consent MYELO-CAN ABX exclusion criteria:
- Fever/infection within 1 month of chemotherapy initiation
- C-difficile infection within 12 months of chemotherapy initiation
- Known sensitivity/allergy to fluoroquinolones
- History of tendon disorders related to fluoroquinolone administration
- Seizure disorder
- Myasthenia gravis
- Pregnancy and/or breastfeeding
Where this trial is running
- CancerCare Manitoba, Winnipeg, Manitoba, Canada
Who to contact
Brett Houston, MD, PhD · 204-787-8552 · bhouston@cancercare.mb.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07528417.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.